QuiaPEG Pharmaceuticals Holding
0.097 SEKBe the first to follow this company
QuiaPEG Pharmaceuticals operates in medical technology. The company has developed a technological platform that is used to develop existing pharmaceuticals. The technology is based on what is known as PEGylation, a technique that connects water-soluble polymers with the pharmaceuticals and is used to improve various characteristics in the biopharmaceuticals in regards to stability and resistance.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
QUIA
Daily low / high price
-
Market cap
7.2M SEK
Turnover
-
Volume
-
Financial calendar
General meeting
06.05.2024
Interim report
29.08.2024
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Iskander World AB | 10.7 % | 10.7 % |
Nordnet Pensionsförsäkring AB | 4.3 % | 4.3 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
QuiaPEG has submitted a formal application to Nasdaq for the reverse acquisition of Rosemonkey Ltd.
QuiaPEG och Net Zero Infrastucture take next step to a formal license agreement
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools